Evidence map›Paper›PMID 41255229›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Interferon-Driven Biomarkers and Synergistic Therapy for PRMT5 Inhibition in Triple-Negative Breast Cancer.

Ziwen Zhang, Sheyu Zhang, Lu Guo, Yichun Pan, Juan Huang, Yishuai Ji, Jiaqi Tao, Yong Wei, Xiaojia Wang, Qin Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ziwen ZhangZhejiang Cancer Hospital, Division of Breast Cancer, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Sheyu ZhangZhejiang Cancer Hospital, Division of Breast Cancer, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Lu GuoZhejiang Cancer Hospital, Division of Breast Cancer, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Yichun PanZhejiang Cancer Hospital, Division of Breast Cancer, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Juan HuangZhejiang Cancer Hospital, Division of Breast Cancer, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Yishuai JiZhejiang Cancer Hospital, Division of Breast Cancer, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Jiaqi TaoZhejiang Cancer Hospital, Division of Breast Cancer, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Yong WeiZhejiang Cancer Hospital, Division of Breast Cancer, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Xiaojia WangZhejiang Cancer Hospital, Division of Breast Cancer, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Qin WuZhejiang Cancer Hospital, Division of Breast Cancer, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.ORCID https://orcid.org/0000-0002-5365-7482

Funding

National Natural Science Foundation of China 82103287National Natural Science Foundation of China 82372741National Natural Science Foundation of China YQ2022HW01Zhejiang Provincial Key R&D Program 2023SDYXS0003Zhejiang Provincial Medical and Health Science and Technology Program 2022RC118Zhejiang Provincial Natural Science Foundation LR22B050001
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) exhibits heterogeneous responses to PRMT5 inhibition, posing challenges for therapeutic targeting. Here, using PRMT5 inhibitors, coupled with transcriptomic profiling, basal interferon (IFN) signaling is identified as a biomarker of PRMT5 inhibition sensitivity. Sensitive TNBC models are characterized by elevated DNA damage, which correlated with enriched IFN pathway activity. Pharmacologically inducing DNA damage with the PARP inhibitor Olaparib activated IFN signaling and synergistically sensitized resistant TNBC cells to PRMT5 inhibition. Comprehensive pre-clinical validation in patient-derived organoid (PDO) and xenograft (PDX) models demonstrated robust antitumor efficacy of this combination therapy. Moreover, this dual targeting strategy reshaped the tumor microenvironment, enhancing dendritic cell-CD8

Indexed as

Biomarkers, TumorInterferonsProtein-Arginine N-MethyltransferasesTriple Negative Breast NeoplasmsAnimalsCell Line, TumorDrug SynergismFemaleHumansMiceSignal TransductionTumor MicroenvironmentXenograft Model Antitumor AssaysBiomarkers, TumorInterferonsPRMT5 protein, humanProtein-Arginine N-MethyltransferasesbiomarkerDNA damageinterferonPRMT5TNBC

Identifiers

PMID41255229
PMCPMC12866763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.